UKIACR average (population) | UKIACR average (country) | England | Scotland | Wales | Northern Ireland | Republic of Ireland | |
---|---|---|---|---|---|---|---|
All invasive xnmsc | 46.7% | 45.2% | 47.7% | 42.1% | 38.7% | 54.3% | 43.1% |
All xnmsc 0-24 | 48.5% | 47.7% | 49.2% | 49.4% | 47.3% | 55.1% | 37.4% |
All xnmsc 25-59 | 63.6% | 61.1% | 64.9% | 60.5% | 54.7% | 69.5% | 56.0% |
All xnmsc 60-79 | 46.5% | 44.5% | 47.7% | 41.0% | 39.0% | 54.0% | 40.6% |
All xnmsc 80+ | 28.9% | 27.8% | 29.7% | 23.5% | 22.7% | 35.3% | 27.7% |
Haematology | 6.0% | 8.4% | 5.3% | 3.8% | 14.1% | 9.2% | 9.7% |
Head and Neck | 52.0% | 49.6% | 53.5% | 44.2% | 47.9% | 53.6% | 48.7% |
Lower GI | 65.5% | 66.0% | 66.0% | 64.9% | 56.8% | 82.8% | 59.5% |
Upper GI | 32.9% | 27.6% | 36.5% | 15.4% | 10.6% | 49.0% | 26.4% |
HPB | 29.3% | 26.3% | 31.7% | 13.3% | 10.8% | 45.4% | 30.0% |
Trachea, Bronchus & Lung | 22.2% | 19.7% | 23.8% | 13.1% | 16.1% | 27.7% | 17.9% |
Melanoma | 92.3% | 90.9% | 92.5% | 98.1% | 85.8% | 89.6% | 88.6% |
Breast | 75.9% | 74.5% | 76.7% | 76.6% | 70.7% | 84.5% | 64.2% |
Cervix | 58.6% | 50.9% | 64.2% | 26.9% | 44.0% | 61.7% | 57.4% |
Other Female Genitals | 72.3% | 68.5% | 73.8% | 69.9% | 57.6% | 74.5% | 66.9% |
Prostate | 21.5% | 18.6% | 22.3% | 15.8% | 14.3% | 17.8% | 22.9% |
Kidney | 59.3% | 59.2% | 59.9% | 55.2% | 48.8% | 75.5% | 56.8% |
Bladder | 81.6% | 75.3% | 84.0% | 77.4% | 77.3% | 87.8% | 50.0% |
Brain and CNS | 48.3% | 51.7% | 47.1% | 55.1% | 38.1% | 58.4% | 59.6% |
Thyroid & other endocrine glands | 79.1% | 75.4% | 80.6% | 77.7% | 65.6% | 86.2% | 67.1% |
CUP | 13.1% | 11.7% | 14.4% | 6.8% | 8.0% | 19.6% | 9.5% |
Other invasive cancer | 51.1% | 49.1% | 52.4% | 45.4% | 42.0% | 56.8% | 48.7% |
Breast in situ | 85.0% | 84.4% | 85.5% | 94.2% | 77.1% | 95.8% | 69.4% |
Cervix in situ | 82.3% | 63.7% | 87.9% | 85.3% | 58.5% | 13.3% | 73.4% |
Other tumours | 58.8% | 54.4% | 60.4% | 60.9% | 39.4% | 47.6% | 63.3% |
Non-Melanoma Skin Cancer | 50.7% | 71.1% | 43.1% | 89.5% | 85.3% | 56.4% | 80.9% |